Genomtec S.A. (WSE:GMT)

Genomtec Statistics

Total Valuation

Genomtec has a market cap or net worth of PLN 90.24 million. The enterprise value is 82.73 million.

Market Cap	90.24M
Enterprise Value	82.73M

Important Dates

The last earnings date was Monday, September 29, 2025.

Earnings Date	Sep 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Genomtec has 15.06 million shares outstanding. The number of shares has increased by 14.76% in one year.

Current Share Class	15.06M
Shares Outstanding	15.06M
Shares Change (YoY)	+14.76%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	9.00%
Owned by Institutions (%)	3.32%
Float	12.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8,203.38
PB Ratio	6.99
P/TBV Ratio	6.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-7.06
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.18.

Current Ratio	3.53
Quick Ratio	3.19
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-83.11

Financial Efficiency

Return on equity (ROE) is -91.34% and return on invested capital (ROIC) is -47.21%.

Return on Equity (ROE)	-91.34%
Return on Assets (ROA)	-32.71%
Return on Invested Capital (ROIC)	-47.21%
Return on Capital Employed (ROCE)	-72.51%
Revenue Per Employee	423
Profits Per Employee	-450,885
Employee Count	26
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

In the past 12 months, Genomtec has paid 1,000 in taxes.

Income Tax	1,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.91% in the last 52 weeks. The beta is 0.23, so Genomtec's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	-29.91%
50-Day Moving Average	6.43
200-Day Moving Average	7.07
Relative Strength Index (RSI)	35.85
Average Volume (20 Days)	11,914

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genomtec had revenue of PLN 11,000 and -11.72 million in losses. Loss per share was -0.79.

Revenue	11,000
Gross Profit	-6.88M
Operating Income	-11.55M
Pretax Income	-11.72M
Net Income	-11.72M
EBITDA	-8.94M
EBIT	-11.55M
Loss Per Share	-0.79

Balance Sheet

The company has 9.88 million in cash and 2.37 million in debt, giving a net cash position of 7.51 million or 0.50 per share.

Cash & Cash Equivalents	9.88M
Total Debt	2.37M
Net Cash	7.51M
Net Cash Per Share	0.50
Equity (Book Value)	12.90M
Book Value Per Share	0.87
Working Capital	8.47M

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-105,018.18%
Pretax Margin	-106,563.64%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Genomtec does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.76%
Shareholder Yield	-14.76%
Earnings Yield	-12.99%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genomtec has an Altman Z-Score of 7.59 and a Piotroski F-Score of 2.

Altman Z-Score	7.59
Piotroski F-Score	2